Shinichi Oka - Concepedia

Author

Shinichi Oka

National Center for Global Health and Medicine ORCID

Also Known As

A. Mouglignier, Akihiro Inui, Do Duy Cuong, G Schmutz, J Tanuma, J. Lee, K Tazoe, McMichael, Andrew J, Oka, Shinichi, S OKA

696

Publications

14.4K

Citations

H-Index

194

Concepts

All Affiliations

National Center for Global Health and Medicine Kumamoto University Saitama International Medical Center National Institute of Infectious Diseases The University of Tokyo

About

Shinichi Oka is an author at National Center for Global Health and Medicine specializing in medicine, hiv, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	38	114	5.4K
2	Natural Sciences	7	7	405
3	Health Sciences	5	5	201
4	Engineering	3	3	121
5	Nursing	1	1	25

Shinichi Oka

301

Publications

12.6K

Citations

H-Index

Page 1

	Year	Citations
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials Paul E. Sax, David A. Wohl, Michael T. Yin, The Lancet Treatment And PreventionMedicineAntiviral Drug DevelopmentClinical TrialsAntiviral Therapy	2015	593
Adaptation of HIV-1 to human leukocyte antigen class I Yuka Kawashima, Katja Pfafferott, John Frater, Nature Primary ImmunodeficiencyHuman RetrovirusImmunologyAntiviral ResponseHiv	2009	464
Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection Chloe Orkin, Keikawus Arastéh, Miguel Górgolas Hernández-Mora, New England Journal of Medicine	2020	427
Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens K. Tsuchiya, Hiroyuki Gatanaga, Natsuo Tachikawa, Biochemical and Biophysical Research Communications Viral PersistenceHuman RetrovirusImmunologyHiv-1 PatientsHigh Plasma	2004	272
Successful Efavirenz Dose Reduction in HIV Type 1-Infected Individuals with Cytochrome P450 2B6 6 and 26 Hiroyuki Gatanaga, Tsunefusa Hayashida, K. Tsuchiya, Clinical Infectious Diseases	2007	222
Metagenomic Identification of Microbial Signatures Predicting Pancreatic Cancer From a Multinational Study Naoyoshi Nagata, Suguru Nishijima, Yasushi Kojima, Gastroenterology	2022	200
Induction of IFN-λ3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection Kazumoto Murata, Mai Asano, Akihiro Matsumoto, Gut	2016	187
Brief Report David A. Wohl, Shinichi Oka, Nathan Clumeck, JAIDS Journal of Acquired Immune Deficiency Syndromes Double-blinded Phase 3Initial Hiv-1 TreatmentTaf ArmTreatment And PreventionMedicine	2016	178
Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study Chloe Orkin, Shinichi Oka, Patrick Philibert, The Lancet HIV Treatment And PreventionMedicineAntiviral Drug DevelopmentAntiviral TherapyPharmacotherapy	2021	166
Population-level Metagenomics Uncovers Distinct Effects of Multiple Medications on the Human Gut Microbiome Naoyoshi Nagata, Suguru Nishijima, Tohru Miyoshi‐Akiyama, Gastroenterology	2022	157

Page 1